Yes, increase dapagliflozin to 10 mg daily in this patient with CKD stage 3B
For patients with CKD stage 3B (eGFR 30-44 mL/min/1.73 m²), the recommended dose of dapagliflozin is 10 mg daily when used for kidney and cardiovascular protection, not the 5 mg dose typically used for glycemic control alone. 1
Dosing Algorithm for Dapagliflozin in CKD Stage 3B
If the indication is kidney/cardiovascular protection (not just glycemic control):
- eGFR 30-44 mL/min/1.73 m²: Use 10 mg daily 1, 2
- The FDA label explicitly states that for CKD and heart failure indications, the dose is 10 mg once daily when eGFR is ≥25 mL/min/1.73 m² 2
If the indication is glycemic control only:
- Dapagliflozin is not recommended for glucose lowering when eGFR <45 mL/min/1.73 m² as it becomes ineffective for this purpose 3, 2
- However, this does NOT mean you should stop it—you should continue it at 10 mg for kidney/cardiovascular benefits
Key Evidence Supporting Dose Increase
The 2022 ADA/KDIGO consensus guidelines are unequivocal: dapagliflozin should be dosed at 10 mg daily in CKD stage 3B 1. This recommendation applies regardless of diabetes status, as the kidney and cardiovascular protective effects persist even when glucose-lowering efficacy diminishes.
The Mayo Clinic guideline reinforces this: for heart failure or CKD indications with eGFR 25 to <45 mL/min/1.73 m², the dose is 10 mg 3. The FDA label confirms that 10 mg is the appropriate dose for reducing sustained eGFR decline, kidney failure, cardiovascular death, and hospitalization for heart failure in patients with CKD 2.
Clinical Rationale
The glucose-lowering effect of SGLT2 inhibitors declines as kidney function worsens, but the kidney and cardiovascular protective benefits are preserved 1. This is a critical distinction that changes the therapeutic goal from glycemic control to organ protection.
Research data support this approach:
- Pharmacokinetic studies show dapagliflozin exposure increases with declining kidney function, but this does not require dose reduction 4, 5
- In patients with eGFR 15-30 mL/min/1.73 m², no clinically significant accumulation occurred with 10 mg daily dosing 5
- Clinical studies in CKD stage 3A (eGFR 45-59) demonstrated safety and efficacy with 10 mg dosing 6
- Real-world data show effectiveness in preventing renal function decline even in patients with eGFR <25 mL/min/1.73 m² 7
Important Caveats
Do NOT increase the dose if:
- eGFR is <25 mL/min/1.73 m² at initiation (though you can continue 10 mg if already established) 1, 2
- Patient is on dialysis (contraindicated) 3, 2
- Patient has polycystic kidney disease or recent immunosuppressive therapy for kidney disease 2
Monitor for:
- Initial eGFR dip: A reversible decrease in eGFR of 2-5 mL/min/1.73 m² typically occurs within 2-4 weeks but returns toward baseline—this is hemodynamic and NOT a reason to stop 1
- Volume depletion: Assess volume status and consider reducing diuretics before increasing the dose 1
- Ketoacidosis risk: Withhold during prolonged fasting, surgery, or critical illness 1
- Genital mycotic infections: More common in women (6% vs 1% placebo) 1
Once initiated at 10 mg:
- Continue even if eGFR falls below 25 mL/min/1.73 m² until dialysis initiation 1, 2
- The kidney and cardiovascular benefits justify continuation despite loss of glucose-lowering effect 1
Bottom Line
Your patient on dapagliflozin 5 mg with CKD stage 3B is underdosed for kidney protection. Increase to 10 mg daily to achieve the proven benefits of reducing sustained eGFR decline, kidney failure, cardiovascular death, and heart failure hospitalization 1, 2. The 5 mg dose is appropriate only for initial glycemic control in patients with eGFR ≥45 mL/min/1.73 m²—below this threshold, the therapeutic target shifts from glucose lowering to organ protection, requiring the 10 mg dose.